Dizziness postural adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 9,458 adverse event reports that record the MedDRA preferred term Dizziness postural. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 839 reports in the 12 months to June 2026 and 738 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 697 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 839 (0.1%) record this term. Reports for male patients were 42.8% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 94 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Dizziness postural name as a suspect product, in order of name
Drug	Class	Reports with this term
Adempas	Soluble guanylate cyclase stimulator	179
Ambrisentan	Endothelin receptor antagonist	129
Amlodipine	Calcium channel blocker	89
Ampyra	Potassium channel blocker	26
Apixaban	Factor Xa inhibitor	25
Aspirin	Nonsteroidal anti-inflammatory drug	74
Atorvastatin		53
Avonex	Interferon beta	26
Bisoprolol	beta-Adrenergic blocker	29
Carvedilol	alpha-Adrenergic blocker	58
Ciprofloxacin	Fluoroquinolone antibacterial	26
Citalopram	Serotonin reuptake inhibitor	28
Clonazepam	Benzodiazepine	31
Cymbalta		80
Digoxin	Cardiac glycoside	39
Dupixent	Interleukin-4 receptor alpha antagonist	87
Eligard	Gonadotropin releasing hormone receptor agonist	40
Eliquis	Factor Xa inhibitor	44
Enbrel	Tumor necrosis factor blocker	105
Entresto	Angiotensin 2 receptor blocker	661
Filspari	Angiotensin 2 receptor blocker	106
Finasteride	5-alpha reductase inhibitor	27
Forteo	Parathyroid hormone analog	147
Fosamax	Bisphosphonate	25
Furosemide	Loop diuretic	87
Gabapentin	Anti-epileptic agent	62
Gilenya	Sphingosine 1-phosphate receptor modulator	164
Gocovri	Influenza A M2 protein inhibitor	36
Humira		126
Ibrance	Kinase inhibitor	53
Imbruvica	Kinase inhibitor	42
Incivek		25
Inflectra	Tumor necrosis factor blocker	39
Infliximab	Tumor necrosis factor blocker	28
Invokana	Sodium-Glucose cotransporter 2 inhibitor	30
Jakafi	Janus kinase inhibitor	86
Jardiance	Sodium-Glucose cotransporter 2 inhibitor	54
Lasix	Loop diuretic	40
Letairis	Endothelin receptor antagonist	50
Lisinopril	Angiotensin converting enzyme inhibitor	76
Losartan	Angiotensin 2 receptor blocker	35
Lyrica		71
Methotrexate	Folate analog metabolic inhibitor	44
Metoprolol	beta-Adrenergic blocker	86
Morphine	Opioid agonist	43
Mounjaro	GLP-1 receptor agonist	37
Northera		122
Nuplazid	Atypical antipsychotic	64
Ofev	Kinase inhibitor	39
Omalizumab	Anti-IgE	46
Opsumit	Endothelin receptor antagonist	149
Orenitram	Prostacycline vasodilator	132
Orgovyx	Gonadotropin releasing hormone receptor antagonist	106
Ozempic	GLP-1 receptor agonist	38
Pantoprazole	Proton pump inhibitor	27
Paracetamol		29
Paroxetine	Serotonin reuptake inhibitor	26
Pegasys	Interferon alpha	45
Pomalyst	Thalidomide analog	41
Pradaxa	Direct thrombin inhibitor	27
Prednisone	Corticosteroid	38
Ramipril	Angiotensin converting enzyme inhibitor	44
Remodulin	Prostacycline vasodilator	170
Repatha	PCSK9 inhibitor	44
Revlimid	Thalidomide analog	114
Ribavirin	Nucleoside analog antiviral	47
Rosuvastatin	HMG-CoA reductase inhibitor	29
Sandostatin	Somatostatin analog	35
Sandostatin LAR Depot		47
Seroquel	Atypical antipsychotic	33
Sertraline	Serotonin reuptake inhibitor	38
Simvastatin	HMG-CoA reductase inhibitor	25
Spironolactone	Aldosterone antagonist	51
Tadalafil	Phosphodiesterase 5 inhibitor	41
Tamsulosin		38
Tamsulosin hydrochloride	alpha-Adrenergic blocker	26
Tecfidera		39
Tracleer	Endothelin receptor antagonist	37
Treprostinil	Prostacycline vasodilator	35
Tymlos		126
Tysabri	Integrin receptor antagonist	37
Tyvaso	Prostacycline vasodilator	146
Tyvaso DPI	Prostacycline vasodilator	112
Uptravi	Prostacyclin receptor agonist	96
Vedolizumab	Integrin receptor antagonist	36
Velcade	Proteasome inhibitor	27
Veletri	Prostacycline vasodilator	27
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	28
Vioxx		33
Vyndamax		45
Xarelto	Factor Xa inhibitor	49
Xeljanz	Janus kinase inhibitor	39
Xolair	Anti-IgE	40
Xtandi	Androgen receptor inhibitor	57

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 40 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Dizziness postural name, in order of name
Class	Reports with this term
Aldosterone antagonist	62
alpha-Adrenergic blocker	115
Androgen receptor inhibitor	69
Angiotensin 2 receptor blocker	878
Angiotensin converting enzyme inhibitor	132
Anti-epileptic agent	101
Anti-IgE	86
Aromatic amino acid	61
Atypical antipsychotic	283
Benzodiazepine	79
beta-Adrenergic blocker	214
Calcium channel blocker	102
CD20-directed cytolytic antibody	56
Corticosteroid	105
Endothelin receptor antagonist	377
Factor Xa inhibitor	122
Folate analog metabolic inhibitor	63
GLP-1 receptor agonist	144
Gonadotropin releasing hormone receptor antagonist	106
HMG-CoA reductase inhibitor	96
Integrin receptor antagonist	73
Interleukin-4 receptor alpha antagonist	91
Janus kinase inhibitor	149
Kinase inhibitor	270
Loop diuretic	150
Nonsteroidal anti-inflammatory drug	142
Opioid agonist	165
Parathyroid hormone analog	149
Phosphodiesterase 5 inhibitor	104
Prostacyclin receptor agonist	98
Prostacycline vasodilator	637
Proton pump inhibitor	64
Serotonin and norepinephrine reuptake inhibitor	66
Serotonin reuptake inhibitor	195
Sodium-Glucose cotransporter 2 inhibitor	118
Soluble guanylate cyclase stimulator	184
Somatostatin analog	50
Sphingosine 1-phosphate receptor modulator	183
Thalidomide analog	178
Tumor necrosis factor blocker	201

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Dizziness postural, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Dizziness postural
Age	Reports	Share
Under 2	1	under 0.1%
2 to 11	12	0.1%
12 to 17	81	0.9%
18 to 44	1,097	11.6%
45 to 64	2,234	23.6%
65 to 74	1,542	16.3%
75 and over	1,435	15.2%
Age not given	3,056	32.3%

Sex of the patient in the reports that record Dizziness postural
Sex	Reports	Share
Female	4,701	49.7%
Male	4,050	42.8%
Unknown or not given	707	7.5%

Age and sex are as the report gives them. 67.6% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Dizziness postural: adverse event reports that record this term. https://reportedreactions.com/reaction/dizziness-postural/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Dizziness postural mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page